Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5741803 | WOODWARD | Substituted thiazolidinedionle derivatives |
Apr, 2015
(9 years ago) | |
US5741803 (Pediatric) | WOODWARD | Substituted thiazolidinedionle derivatives |
Oct, 2015
(8 years ago) | |
US6288095 | WOODWARD | Compounds |
Feb, 2017
(7 years ago) | |
US6288095 (Pediatric) | WOODWARD | Compounds |
Aug, 2017
(6 years ago) | |
US7358366 | WOODWARD | Thiazolidinedione derivative and its use as antidiabetic |
Apr, 2020
(4 years ago) | |
US7358366 (Pediatric) | WOODWARD | Thiazolidinedione derivative and its use as antidiabetic |
Oct, 2020
(3 years ago) |
Market Authorisation Date: 25 May, 1999
Treatment: Use of avandia as monotherapy, in combination with metformin, and in combination with sulfonylureas to improve glycemic control in patients with type 2 diabetes mellitus; Method of treatment of type i...
Dosage: TABLET;ORAL